Innate Pharma (Innate Pharma) Ending Cash Position : $77.00 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Ending Cash Position?

Innate Pharma's Ending Cash Position for the quarter that ended in Dec. 2023 was $77.00 Mil.

Innate Pharma's quarterly Ending Cash Position declined from Dec. 2022 ($89.22 Mil) to Jun. 2023 ($77.37 Mil) and declined from Jun. 2023 ($77.37 Mil) to Dec. 2023 ($77.00 Mil).

Innate Pharma's annual Ending Cash Position declined from Dec. 2021 ($117.24 Mil) to Dec. 2022 ($89.22 Mil) and declined from Dec. 2022 ($89.22 Mil) to Dec. 2023 ($77.00 Mil).

Innate Pharma Ending Cash Position Historical Data

The historical data trend for Innate Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Ending Cash Position Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

225.43

166.41

117.24

89.22

77.00

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															117.24	108.83	89.22	77.37	77.00

Innate Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Innate Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	91.848	+	-14.852
	=	77.00

Innate Pharma's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	77.875	+	-0.879
	=	77.00

Innate Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.